Pri­vate eq­ui­ty firm Per­mi­ra buys phar­ma ser­vice provider Er­gomed in £703.1M deal

Pri­vate eq­ui­ty com­pa­ny Per­mi­ra has ac­quired pub­licly-list­ed phar­ma ser­vice provider Er­gomed in a cash agree­ment worth £703.1 mil­lion ($883 mil­lion), with the deal slat­ed to be­come ef­fec­tive in the first quar­ter of 2024.

“We be­lieve the ac­qui­si­tion will sig­nif­i­cant­ly in­crease our abil­i­ty to in­vest in our com­mer­cial in­fra­struc­ture, tech­nol­o­gy trans­for­ma­tion and to ex­e­cute trans­for­ma­tion­al M&A, in both the CRO and PV busi­ness­es,” said Er­gomed founder Miroslav Rel­janović in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.